Evidence map›Paper›PMID 33563902›Full record

ArticleBlood cancer journal2021

XPO1 inhibitors represent a novel therapeutic option in Adult T-cell Leukemia, triggering p53-mediated caspase-dependent apoptosis.

Eline Boons, Tatiane C Nogueira, Tim Dierckx, Soraya Maria Menezes, Maarten Jacquemyn, Sharon Tamir, Yosef Landesman, Lourdes Farré, Achiléa Bittencourt, Keisuke Kataoka and 5 more

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Translational lung cancer research · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 4 countries.

Eline BoonsKU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, B-3000, Leuven, Belgium.
Tatiane C NogueiraKU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, B-3000, Leuven, Belgium.
Tim DierckxKU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical and Epidemiological Virology, Rega Institute, B-3000, Leuven, Belgium.ORCID 0000-0002-1969-7974
Soraya Maria MenezesKU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical and Epidemiological Virology, Rega Institute, B-3000, Leuven, Belgium.
Maarten JacquemynKU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, B-3000, Leuven, Belgium.ORCID 0000-0003-2626-4189
Sharon TamirKaryopharm Therapeutics, Newton, MA, USA.
Yosef LandesmanKaryopharm Therapeutics, Newton, MA, USA.
Lourdes FarréInstituto de Pesquisa Goncalo Moniz, Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Bahia, Brazil.
Achiléa BittencourtHUPES, Federal University of Bahia (UFBA), Salvador-Bahia, Brazil.
Keisuke KataokaDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.ORCID 0000-0002-8263-9902
Seishi OgawaDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.
Robert SnoeckKU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, B-3000, Leuven, Belgium.
Graciela AndreiKU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, B-3000, Leuven, Belgium.
Johan Van Weyenbergh *KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical and Epidemiological Virology, Rega Institute, B-3000, Leuven, Belgium.ORCID 0000-0003-3234-8426
Dirk Daelemans *KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, B-3000, Leuven, Belgium. dirk.daelemans@kuleuven.be.ORCID 0000-0001-7092-1153
Rega Institute for Medical Research · BEKaryopharm Therapeutics (United States) · USKyoto University · JPFundação Oswaldo Cruz · BRUniversidade Federal da Bahia · BR

Funding

Fonds Wetenschappelijk Onderzoek (Research Foundation Flanders) G0D6817NFonds Wetenschappelijk Onderzoek (Research Foundation Flanders) PhD grantJapan Agency for Medical Research and Development (AMED) JP119cm0106501h0004KU Leuven (Katholieke Universiteit Leuven) Vaast Leysen Leerstoel voor Infectieziekten in OntwikkelingslandenKyoto University KAKENHI 15H05909
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsApoptosisCell Line, TumorExportin 1 ProteinHumansHydrazinesKaryopherinsLeukemia-Lymphoma, Adult T-CellReceptors, Cytoplasmic and NuclearTriazolesTumor Suppressor Protein p53Antineoplastic AgentsExportin 1 ProteinHydrazinesKaryopherinsReceptors, Cytoplasmic and NuclearselinexorTriazolesTumor Suppressor Protein p53

Identifiers

PMID33563902
PMCPMC7873181
OpenAlexW3126520642

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.